LOS ANGELES, CA - HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced today that it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter results for the period ended March 31, 2026. The company also plans to provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and AI programs.
The announcement comes as HeartBeam advances its platform technology, which the company describes as the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a 12-lead ECG. This technology is designed for portable devices that can be used wherever the patient is, with the goal of delivering actionable heart intelligence. Physicians would be able to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility, potentially redefining the future of cardiac health management.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology enablement. These regulatory milestones underpin the company's limited commercial launch and ongoing product development efforts.
The upcoming call will likely address progress on the extended-wear patch, which could expand the company's addressable market by enabling longer-term monitoring. Additionally, updates on heart attack detection and AI programs are expected to highlight how the company is leveraging artificial intelligence to improve diagnostic accuracy and clinical decision-making. For investors, these updates are critical as they signal the company's trajectory toward broader commercialization and potential revenue generation.
HeartBeam's focus on portable, cable-free cardiac monitoring addresses a growing need for remote patient management, particularly as healthcare systems seek to reduce hospital readmissions and improve access to care. The ability to synthesize a 12-lead ECG from a compact device could enable earlier detection of acute conditions like heart attacks, potentially saving lives and reducing healthcare costs.
Investors and industry observers will be watching for details on the commercial launch's early adoption, any partnerships, and the timeline for the extended-wear patch. The company's financial results will also be scrutinized for cash burn rate and runway, as is typical for pre-revenue medtech firms.
The full press release is available at https://ibn.fm/yN939. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.
Forward-looking statements in the release are subject to risks and uncertainties, as detailed in the company's filings with the SEC. The conference call will provide an opportunity for analysts and shareholders to assess the company's progress and outlook.
